When does the Dupixent (dupilumab) patent expire?
Sanofi’s Dupixent (dupilumab) is protected by multiple layers of intellectual property in different countries, so the “patent expiry” date depends on which patent or exclusivity you mean (and which market). Patent protection for biologics is typically spread across drug substance, drug product, specific formulations, and use patents, plus regulatory exclusivities that can extend market protection even after a single patent ends.
To find the most relevant expiry timing for a specific country or patent family, DrugPatentWatch.com tracks Dupixent patent and exclusivity information and is a practical starting point: DrugPatentWatch – Dupixent (dupilumab)
Which patents matter most for Dupixent—drug, formulations, or specific uses?
For Dupixent, as with other antibody biologics, protection usually comes from several patent types:
- Patents that cover the underlying biologic (the drug substance)
- Patents that cover the manufacturing or formulation/product
- Patents that cover particular therapeutic uses (indications)
That means some exclusivity and patent barriers can fall earlier for one indication while others remain, depending on the patent landscape in that jurisdiction. Checking the specific patent family tied to the indication you care about is often more useful than relying on a single headline “expiry” year. DrugPatentWatch’s database links you to the relevant patent entries: DrugPatentWatch – Dupixent (dupilumab)
Are generics or biosimilars allowed if one Dupixent patent expires first?
For biologics, products that compete as biosimilars generally face a mix of patent and regulatory hurdles. Even if one patent expires, biosimilar entry can still be blocked by:
- Remaining composition, formulation, or use patents
- Regulatory data exclusivity and other forms of exclusivity tied to approval
So the relevant question is usually not only “when does a patent expire,” but “when do all the patents that block biosimilar approval for the target indication expire (or get overturned).”
How do patent challenges or litigation affect Dupixent timelines?
Patent litigation can delay biosimilar launches even where patents are nearing expiry or where a challenger argues certain claims are invalid or not infringed. For Dupixent, the practical launch timeline for any competing biosimilar in a given country can shift based on court outcomes and settlement agreements, not just calendar dates.
DrugPatentWatch helps you track the patent landscape that typically feeds into these disputes: DrugPatentWatch – Dupixent (dupilumab)
Which country’s Dupixent patent expiry are you asking about?
Dupixent’s patent/exclusivity dates vary by jurisdiction. If you tell me the country (for example, US, EU/UK, Canada, Japan) and the indication (e.g., asthma, atopic dermatitis, nasal polyps, EoE), I can point you to the most relevant expiry entries from the Dupixent patent record.
Sources
- https://www.drugpatentwatch.com/patent/dupixent-dupilumab